Total
0
Shares
Imugene (ASX:IMU) - CEO, Leslie Chong - The Market Herald
CEO, Leslie Chong
Source: Imugene
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imugene (IMU) has entered a licensing agreement with City of Hope for the patents covering a novel combination immunotherapy
  • The therapy releases a CD19 expressing oncolytic, or 'cancer cell destroying' virus to enable CD19 directed chimeric antigen receptor (CAR) T cell therapies to target solid tumours
  • The patents cover the cell therapy technology developed at the City of Hope independent cancer research and treatment centre near Los Angeles
  • Under the agreement, Imugene will acquire the exclusive worldwide rights to develop and commercialise the patents covering CF33-CD19
  • Imugene’s managing director and CEO, Leslie Chong said the platform will open up the entire field of use to cellular therapy for the CF33 oncolytic virus
  • The company anticipates trials of the treatment to begin in 2022
  • Shares are up 7.58 per cent and are trading at 35.5 cents

Imugene (IMU) has entered a licensing agreement with LA-based cancer centre, City of Hope, for the patents covering a novel combination immunotherapy.

The therapy releases a CD19 expressing oncolytic, or 'cancer cell destroying' virus to enable CD19-directed chimeric antigen receptor (CAR) T cell therapies to target solid tumours.

Trials of the treatment are anticipated to begin in 2021.

The patents cover the cell therapy technology which includes CF33-CD19, otherwise known as onCARlytics, or an agent that tags cancer cells for CAR T cell destruction which was developed at the City of Hope independent cancer research and treatment centre near Los Angeles.

Under the agreement, Imugene will acquire the exclusive worldwide rights to develop and commercialise the patents covering CF33-CD19.

The company has agreed to pay City of Hope license fees made up of an upfront, annual maintenance fee which will be creditable against future royalty payments, performance-based consideration as well as net sales based on single digit royalty payments, and sub-licensing fees.

A separate four year sponsored research agreement with City of Hope and the research team led by Dr.Priceman to further develop the technology has also been executed.

Imugene’s managing director and CEO, Leslie Chong said the platform will open up the entire field of use to cellular therapy for the CF33 oncolytic virus.

"Supercharging CF33 with CD19 is a revolutionary new paradigm in combination therapy with any CD19 binding therapies to include bi-specifics, antibody drug conjugates and CAR T, cell therapy for solid tumours," she said.

"The CAR T cell field currently only treats around 10 per cent of all cancers such as blood or liquid tumours, whereas this technology has the potential to open up the solid tumour market,” she continued.

Yuman Fong, M.D., professor and Sangiacomo Family Chair in Surgical
Oncology at City of Hope was involved in the research collaboration and explained the team's work.

"Our City of Hope team designed this CF33 oncolytic virus to do what it does
so well. It enters the cancer cell, uses the cell’s own machinery to replicate itself, and engineer the cancer cells to express the well-known CAR T cell target, CD19,” Fong said.

The company expects to begin a phase one clinical trial in 2022.

Shares are trading 7.58 per cent higher at 35.5 cents at 10:27 am AEST.

IMU by the numbers
More From The Market Herald
Gabon-focussed iron ore company Genmin (ASX:GEN) lists on ASX

" Argenica Therapeutics (ASX:AGN) lists on ASX

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.